Latest Thyroid neoplasm Stories
Exelixis, Inc. (Nasdaq:EXEL) today announced that it has notified GlaxoSmithKline (GSK) that it has achieved proof-of-concept for XL184 under the collaboration agreement between GSK and Exelixis, and has submitted the corresponding data report to GSK.
By Megan Williams, The Free Lance-Star, Fredericksburg, Va. Jul. 27--When Anita Kaissi found herself feeling constantly sluggish, she thought it was because she had just had a baby.
San Francisco-based biotech Exelixis has seen its shares rise after taking an investigational thyroid cancer drug into a Phase III trial.
Exelixis has initiated the Phase III registration trial of XL184 as a potential treatment for medullary thyroid cancer.
Exelixis, Inc. (Nasdaq:EXEL) announced today that the phase 3 registration trial of XL184 as a potential treatment for medullary thyroid cancer (MTC) has been initiated. XL184 is a small molecule anticancer compound targeting the MET, RET, and VEGFR2 receptor tyrosine kinases.
WALTHAM, Mass., July 17, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc.
By Fisher, Ronald E Siegel, Barry A; Edell, Steven L; Oyesiku, Nelson M; Morgenstern, David E; Messmann, Richard A; Amato, Robert J ^sup 99m^Tc-EC20 is a folate receptor (FR)-targeted imaging agent consisting of the vitamin folate conjugated to ^sup 99m^Tc.
SOUTH SAN FRANCISCO, Calif., June 16 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that the company and the U.S.
A new European study published this week surmises that weight gain increases the risk of developing most types of cancer.
By Delikoukos, Stylianos Mantzos, Fotios Isolated thyroid gland injury due to blunt neck trauma is uncommon and rarely complicated by thyroid storm in patients without known hyperthyroidism.